Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation

Transplant International

Volumn 22, Issue 8, 2009, Pages 821-830

  Shehata, Magdi ^a,b   Bhandari, Sunil ^c   Venkat Raman, Gopalakrishnan ^d   Moore, Richard ^e   D'Souza, Richard ^f   Riad, Hany ^g   Bakran, Ali ^h   Baker, Richard ⁱ   Needham, Christine ^j   Andrews, Christopher ^j  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^d QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^e Cardiff Royal Infirmary   (United Kingdom)

^f ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^g MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^h ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j Novartis Pharmaceuticals UK Ltd   (United Kingdom)

more..

Author keywords

Dose; Enteric coated mycophenolate sodium; Gastrointestinal; Mycophenolate mofetil; Myfortic

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ENTERIC COATED TABLET; FEMALE; FLATULENCE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GINGIVA PAIN; HEADACHE; HUMAN; INDIGESTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SIDE EFFECT; STOMACH DISEASE; VOMITING;

ADULT; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED;

EID: 67651160692     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00877.x     Document Type: Article

References (25)

1. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006 6 : 1111.
2. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003 14 : 2381.
3. Pelletier RP, Akin B, Henry ML, Elkhammas EA, Rajab A, Ferguson RM. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003 17 : 200.
4. Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients. Clin Transplant 2005 19 : 779.
5. Shah S, Collett D, Johnson R, Raftery M, Rudge C, Yaqoob MM. The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United Kingdom. Transplantation 2008 86 : 1035.
6. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006 82 : 102.
7. Hardinger K, Brennan DC, Lowell J, Schnitzler M. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004 17 : 609.
8. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004 4 : 231.
9. Budde K, Curtis J, Knoll G, et al., on behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004 4 : 237.
10. Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006 81 : 1290.
11. Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007 84 : 1443.
12. Sollinger H, Leverson G, Voss B, Pirsch J. Myfortic vs. Cellcept: a large, single-center comparison. Am J Transplant 2008 8 (Suppl. 2 514. Abstract 1263
13. Budde K, Tuncer M, El-Shahawy M, on behalf of the DIRECT Study Group. Dose and dose adjustments of mycophenolate sodium (EC-MPS, myfortic) and mycophenolate mofetil (MMF) in de novo renal transplant patients. Transplantation 2006 82 (Suppl. 3 345.
14. de Paula Meneses R, Halusch Kotsifas C. Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in paediatric renal transplant patients with stable graft function. Pediatr Transplant 2009 13 : 188.
15. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993 28 : 681.
16. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995 30 : 1046.
17. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998 7 : 75.
18. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995 82 : 216.
19. Kleinman L, Kilburg A, Machnicki G, et al. Using GI-specific patient outcomes measures in renal transplant patients: validation of the GSRS and GIQLI. Qual Life Res 2006 15 : 1223.
20. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473.
21. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993 2 : 217.
22. Heaton K. The Bristol Stool form Scale. In : Understanding your Bowels. Family Doctor Publications in association with the British Medical Association. 1999, London. ISBN 1-898205-08-6.
23. Opelz G, Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year post transplant. Transplantation 2008 86 : 371.
24. Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation 2008 86 : 761.
25. Massari P, Duro-Garcia V, Girón F, et al., myPROMS LatAm Study Group. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005 37 : 916.